Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation

Authors:

Abstract
Congestive heart failure (CHF) is commonly associated with atrial fibrillation (AF), and their combined presentation confers a worse prognosis than either condition alone.1 Treatment of both conditions implies use of specific drugs for CHF plus antithrombotic agents for stroke prevention. In addition, management strategies and outcomes may be affected by the etiology of CHF, namely ischemic cardiomyopathy (ICM) or nonischemic cardiomyopathy (NICM) because the prescription of antithrombotic therapies might be different and could affect prognosis in terms of death, stroke/systemic embolism (SE), and bleeding.2,3 The aim of our study was to assess the treatment strategies in terms of antithrombotic and CHF therapies and 1-year clinical outcomes in patients with newly diagnosed AF and concomitant CHF stratified by etiology (ICM vs NICM) enrolled in the Global Anticoagulant Registry in the Field–Atrial Fibrillation (GARFIELD-AF) registry.

This publication has 37 references indexed in Scilit: